Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study)

Sacubitril/valsartan reduces heart failure (HF)-related hospitalizations and cardiovascular mortality in PARADIGM-HF and has become a foundational treatment for HF with reduced ejection fraction (HFrEF). However, data of its routine real-world use are limited, and evidence from Italian settings is l...

Descripción completa

Detalles Bibliográficos
Autores principales: Di Lenarda, Andrea, Di Gesaro, Gabriele, Sarullo, Filippo Maria, Miani, Daniela, Driussi, Mauro, Correale, Michele, Bilato, Claudio, Passantino, Andrea, Carluccio, Erberto, Villani, Alessandra, degli Esposti, Luca, d’Agostino, Chiara, Peruzzi, Elena, Poli, Simone, Iacoviello, Massimo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863394/
https://www.ncbi.nlm.nih.gov/pubmed/36675628
http://dx.doi.org/10.3390/jcm12020699

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9863394/
https://www.ncbi.nlm.nih.gov/pubmed/36675628
http://dx.doi.org/10.3390/jcm12020699

Ejemplares similares